These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19546811)

  • 1. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.
    Dumond JB; Patterson KB; Pecha AL; Werner RE; Andrews E; Damle B; Tressler R; Worsley J; Kashuba AD
    J Acquir Immune Defic Syndr; 2009 Aug; 51(5):546-53. PubMed ID: 19546811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.
    Adams JL; Patterson KB; Prince HM; Sykes C; Greener BN; Dumond JB; Kashuba AD
    Antivir Ther; 2013; 18(8):1005-13. PubMed ID: 23899439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.
    Cottrell ML; Prince HM; Allmon A; Mollan KR; Hudgens MG; Sykes C; White N; Malone S; Dellon ES; Madanick RD; Shaheen NJ; Patterson KB; Kashuba AD
    J Acquir Immune Defic Syndr; 2016 Aug; 72(5):498-506. PubMed ID: 26999532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial.
    Chen BA; Panther L; Marzinke MA; Hendrix CW; Hoesley CJ; van der Straten A; Husnik MJ; Soto-Torres L; Nel A; Johnson S; Richardson-Harman N; Rabe LK; Dezzutti CS
    J Acquir Immune Defic Syndr; 2015 Nov; 70(3):242-9. PubMed ID: 26034880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
    Lê MP; Belarbi L; Chaix ML; Dulioust E; Mahjoub N; Salmon D; Viard JP; Duvivier C; Peytavin G; Launay O; Ghosn J
    J Antimicrob Chemother; 2017 Nov; 72(11):3167-3171. PubMed ID: 28961979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
    Fox J; Tiraboschi JM; Herrera C; Else L; Egan D; Dickinson L; Jackson A; Olejniczak N; Back D; Khoo S; Shattock R; Boffito M
    J Acquir Immune Defic Syndr; 2016 Nov; 73(3):252-257. PubMed ID: 27727157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.
    Garvey L; Nelson M; Latch N; Erlwein OW; Allsop JM; Mitchell A; Kaye S; Watson V; Back D; Taylor-Robinson SD; Winston A
    J Antimicrob Chemother; 2012 Jan; 67(1):206-12. PubMed ID: 21987241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.
    Brown KC; Patterson KB; Malone SA; Shaheen NJ; Prince HM; Dumond JB; Spacek MB; Heidt PE; Cohen MS; Kashuba AD
    J Infect Dis; 2011 May; 203(10):1484-90. PubMed ID: 21502084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.
    Malcolm RK; Veazey RS; Geer L; Lowry D; Fetherston SM; Murphy DJ; Boyd P; Major I; Shattock RJ; Klasse PJ; Doyle LA; Rasmussen KK; Goldman L; Ketas TJ; Moore JP
    Antimicrob Agents Chemother; 2012 May; 56(5):2251-8. PubMed ID: 22330914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.
    Abel S; Davis JD; Ridgway CE; Hamlin JC; Vourvahis M
    Antivir Ther; 2009; 14(6):831-7. PubMed ID: 19812445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.
    Colbers A; Best B; Schalkwijk S; Wang J; Stek A; Hidalgo Tenorio C; Hawkins D; Taylor G; Kreitchmann R; Burchett S; Haberl A; Kabeya K; van Kasteren M; Smith E; Capparelli E; Burger D; Mirochnick M;
    Clin Infect Dis; 2015 Nov; 61(10):1582-9. PubMed ID: 26202768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc.
    Ramanathan S; Abel S; Tweedy S; West S; Hui J; Kearney BP
    J Acquir Immune Defic Syndr; 2010 Feb; 53(2):209-14. PubMed ID: 19851115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial.
    Dezzutti CS; Richardson-Harman N; Rohan LC; Marzinke MA; Hoesley CJ; Panther L; Johnson S; Nuttall JP; Nel A; Chen BA;
    Medicine (Baltimore); 2016 Jul; 95(28):e4174. PubMed ID: 27428211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques.
    Winters MA; Van Rompay KK; Kashuba AD; Shulman NS; Holodniy M
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4059-63. PubMed ID: 20696881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
    Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
    J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
    Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
    HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
    Pozniak AL; Boffito M; Russell D; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):54-9. PubMed ID: 18333866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
    Vourvahis M; Plotka A; Mendes da Costa L; Fang A; Heera J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6158-64. PubMed ID: 24080663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
    Abel S; Russell D; Whitlock LA; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):47-53. PubMed ID: 18333865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.
    Cottrell ML; Patterson KB; Prince HM; Jones A; White N; Wang R; Kashuba AD
    Antivir Ther; 2015; 20(8):795-803. PubMed ID: 26040011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.